KemPharm’s (NASDAQ:KMPH) “Outperform” Rating Reiterated at CIBC

Share on StockTwits

KemPharm (NASDAQ:KMPH)‘s stock had its “outperform” rating restated by research analysts at CIBC in a report issued on Friday, September 21st.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity set a $11.00 price objective on shares of KemPharm and gave the stock a “buy” rating in a research report on Thursday, May 24th. Cowen cut shares of KemPharm from an “outperform” rating to a “hold” rating in a research report on Monday, July 9th. ValuEngine cut shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research raised shares of KemPharm from a “sell” rating to a “hold” rating in a research report on Thursday, July 12th. Finally, Oppenheimer set a $13.00 price objective on shares of KemPharm and gave the stock a “buy” rating in a research report on Thursday, August 9th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $10.50.

NASDAQ KMPH opened at $2.55 on Friday. The company has a debt-to-equity ratio of -1.05, a quick ratio of 1.76 and a current ratio of 1.76. KemPharm has a 12-month low of $2.46 and a 12-month high of $8.40. The company has a market capitalization of $77.00 million, a PE ratio of -0.86 and a beta of -0.31.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.96) by $0.31. On average, analysts predict that KemPharm will post -2.95 EPS for the current fiscal year.

In other KemPharm news, major shareholder Delaware Street Capital Master bought 304,283 shares of KemPharm stock in a transaction dated Monday, July 30th. The stock was bought at an average price of $4.00 per share, with a total value of $1,217,132.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders bought 2,313,933 shares of company stock valued at $7,242,003. 25.90% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Cowen Inc. acquired a new position in KemPharm in the second quarter valued at about $2,381,000. Millennium Management LLC raised its stake in KemPharm by 878.0% during the second quarter. Millennium Management LLC now owns 151,250 shares of the specialty pharmaceutical company’s stock worth $983,000 after acquiring an additional 135,784 shares in the last quarter. Renaissance Technologies LLC raised its stake in KemPharm by 101.1% during the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock worth $1,182,000 after acquiring an additional 91,400 shares in the last quarter. Spark Investment Management LLC acquired a new position in KemPharm during the second quarter worth about $176,000. Finally, C WorldWide Group Holding A S raised its stake in KemPharm by 3.2% during the second quarter. C WorldWide Group Holding A S now owns 399,999 shares of the specialty pharmaceutical company’s stock worth $2,600,000 after acquiring an additional 12,319 shares in the last quarter. 39.15% of the stock is owned by institutional investors and hedge funds.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

See Also: Stock Symbols and CUSIP Explained

Analyst Recommendations for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.